Patents by Inventor John Maga
John Maga has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230407328Abstract: The present invention provides process for enriching adeno-associated virus particles using anion exchange chromatography and zonal ultracentrifugation.Type: ApplicationFiled: November 2, 2021Publication date: December 21, 2023Applicant: BioMarin Pharmaceutical Inc.Inventors: John MAGA, Harmit VORA, Rahul SHETH, Daniel GOLD, Anant RISHI, Yanhong ZHANG, Kieu TRAN
-
Publication number: 20230241187Abstract: The present invention provides further improved compositions and methods for efficient lysosomal targeting based on the GILT technology. Among other things, the present invention provides methods and compositions for targeting lysosomal enzymes to lysosomes using furin-resistant lysosomal targeting peptides. The present invention also provides methods and compositions for targeting lysosomal enzymes to lysosomes using a lysosomal targeting peptide that has reduced or diminished binding affinity for the insulin receptor.Type: ApplicationFiled: July 27, 2022Publication date: August 3, 2023Inventors: Jonathan LeBowitz, John Maga
-
Publication number: 20220354934Abstract: The present invention provides further improved compositions and methods for efficient lysosomal targeting based on the GILT technology. Among other things, the present invention provides methods and compositions for targeting lysosomal enzymes to lysosomes using furin-resistant lysosomal targeting peptides. The present invention also provides methods and compositions for targeting lysosomal enzymes to lysosomes using a lysosomal targeting peptide that has reduced or diminished binding affinity for the insulin receptor.Type: ApplicationFiled: June 1, 2022Publication date: November 10, 2022Inventors: Jonathan LeBowitz, John Maga
-
Patent number: 11351231Abstract: The present invention provides further improved compositions and methods for efficient lysosomal targeting based on the GILT technology. Among other things, the present invention provides methods and compositions for targeting lysosomal enzymes to lysosomes using furin-resistant lysosomal targeting peptides. The present invention also provides methods and compositions for targeting lysosomal enzymes to lysosomes using a lysosomal targeting peptide that has reduced or diminished binding affinity for the insulin receptor.Type: GrantFiled: July 24, 2017Date of Patent: June 7, 2022Assignee: BIOMARIN PHARMACEUTICAL INC.Inventors: Jonathan LeBowitz, John Maga
-
Publication number: 20210069304Abstract: The present invention provides further improved compositions and methods for efficient lysosomal targeting based on the GILT technology. Among other things, the present invention provides methods and compositions for targeting lysosomal enzymes to lysosomes using furin-resistant lysosomal targeting peptides. The present invention also provides methods and compositions for targeting lysosomal enzymes to lysosomes using a lysosomal targeting peptide that has reduced or diminished binding affinity for the insulin receptor.Type: ApplicationFiled: May 8, 2020Publication date: March 11, 2021Inventors: Jonathan LeBowitz, John Maga
-
Publication number: 20180125949Abstract: The present invention provides further improved compositions and methods for efficient lysosomal targeting based on the GILT technology. Among other things, the present invention provides methods and compositions for targeting lysosomal enzymes to lysosomes using furin-resistant lysosomal targeting peptides. The present invention also provides methods and compositions for targeting lysosomal enzymes to lysosomes using a lysosomal targeting peptide that has reduced or diminished binding affinity for the insulin receptor.Type: ApplicationFiled: July 24, 2017Publication date: May 10, 2018Inventors: Jonathan LeBowitz, John Maga
-
Publication number: 20170007680Abstract: The present invention provides further improved compositions and methods for efficient lysosomal targeting based on the GILT technology. Among other things, the present invention provides methods and compositions for targeting lysosomal enzymes to lysosomes using furin-resistant lysosomal targeting peptides. The present invention also provides methods and compositions for targeting lysosomal enzymes to lysosomes using a lysosomal targeting peptide that has reduced or diminished binding affinity for the insulin receptor.Type: ApplicationFiled: September 23, 2016Publication date: January 12, 2017Inventors: Jonathan LeBowitz, John Maga
-
Patent number: 9469683Abstract: The present invention provides further improved compositions and methods for efficient lysosomal targeting based on the GILT technology. Among other things, the present invention provides methods and compositions for targeting lysosomal enzymes to lysosomes using furin-resistant lysosomal targeting peptides. The present invention also provides methods and compositions for targeting lysosomal enzymes to lysosomes using a lysosomal targeting peptide that has reduced or diminished binding affinity for the insulin receptor.Type: GrantFiled: November 7, 2014Date of Patent: October 18, 2016Assignee: BIOMARIN PHARMACEUTICAL INC.Inventors: Jonathan H. LeBowitz, John Maga
-
Publication number: 20150064157Abstract: The present invention provides further improved compositions and methods for efficient lysosomal targeting based on the GILT technology. Among other things, the present invention provides methods and compositions for targeting lysosomal enzymes to lysosomes using furin-resistant lysosomal targeting peptides. The present invention also provides methods and compositions for targeting lysosomal enzymes to lysosomes using a lysosomal targeting peptide that has reduced or diminished binding affinity for the insulin receptor.Type: ApplicationFiled: November 7, 2014Publication date: March 5, 2015Inventors: Jonathan H. LeBowitz, John Maga
-
Patent number: 8563691Abstract: The present invention provides further improved compositions and methods for efficient lysosomal targeting based on the GILT technology. Among other things, the present invention provides methods and compositions for targeting lysosomal enzymes to lysosomes using furin-resistant lysosomal targeting peptides. The present invention also provides methods and compositions for targeting lysosomal enzymes to lysosomes using a lysosomal targeting peptide that has reduced or diminished binding affinity for the insulin receptor.Type: GrantFiled: February 17, 2012Date of Patent: October 22, 2013Assignee: Biomarin Pharmaceutical, Inc.Inventors: Jonathan LeBowitz, John Maga
-
Publication number: 20120213762Abstract: The present invention provides further improved compositions and methods for efficient lysosomal targeting based on the GILT technology. Among other things, the present invention provides methods and compositions for targeting lysosomal enzymes to lysosomes using furin-resistant lysosomal targeting peptides. The present invention also provides methods and compositions for targeting lysosomal enzymes to lysosomes using a lysosomal targeting peptide that has reduced or diminished binding affinity for the insulin receptor.Type: ApplicationFiled: February 17, 2012Publication date: August 23, 2012Applicant: BIOMARIN PHARMACEUTICAL INC.Inventors: Jonathan H. LeBowitz, John Maga
-
Publication number: 20120093794Abstract: The present invention provides methods for treating Pompe disease in a subject by administering to the subject a therapeutically effective amount of a fusion protein which includes human acid alpha-glucosidase (GAA), or a fragment thereof, and a lysosomal targeting domain. The lysosomal targeting domain binds the human cation-independent mannose-6-phosphate receptor in a mannose-6-phosphate-independent manner.Type: ApplicationFiled: October 7, 2011Publication date: April 19, 2012Applicant: BIOMARIN PHARMACEUTICAL INC.Inventors: Jonathan LeBowitz, John Maga
-
Publication number: 20110223147Abstract: The present invention provides further improved compositions and methods for efficient lysosomal targeting based on the GILT technology. Among other things, the present invention provides methods and compositions for targeting lysosomal enzymes to lysosomes using furin-resistant lysosomal targeting peptides. The present invention also provides methods and compositions for targeting lysosomal enzymes to lysosomes using a lysosomal targeting peptide that has reduced or diminished binding affinity for the insulin receptor.Type: ApplicationFiled: May 7, 2009Publication date: September 15, 2011Applicant: ZYSTOR THERAPEUTICS, INC.Inventors: Jonathan H. Lebowitz, John Maga
-
Patent number: 7785856Abstract: Targeted acid alpha-glucosidase therapeutics that localize to the lysosome are provided. The targeted therapeutics include a therapeutic agent, GAA, and a targeting moiety that binds a receptor on an exterior surface of the cell, permitting proper subcellular localization of the targeted therapeutic upon internalization of the receptor. Nucleic acids, cells, and methods relating to the practice of the invention are also provided.Type: GrantFiled: September 12, 2007Date of Patent: August 31, 2010Assignee: ZyStor Therapeutics, Inc.Inventors: Jonathan LeBowitz, John Maga
-
Publication number: 20090117091Abstract: The present invention provides methods for treating Pompe disease in a subject by administering to the subject a therapeutically effective amount of a fusion protein which includes human acid alpha-glucosidase (GAA), or a fragment thereof, and a lysosomal targeting domain. The lysosomal targeting domain binds the human cation-independent mannose-6-phosphate receptor in a mannose-6-phosphate-independent manner.Type: ApplicationFiled: November 13, 2007Publication date: May 7, 2009Inventors: Jonathan LeBowitz, John Maga
-
Publication number: 20080299640Abstract: Targeted acid alpha-glucosidase therapeutics that localize to the lysosome are provided. The targeted therapeutics include a therapeutic agent, GAA, and a targeting moiety that binds a receptor on an exterior surface of the cell, permitting proper subcellular localization of the targeted therapeutic upon internalization of the receptor. Nucleic acids, cells, and methods relating to the practice of the invention are also provided.Type: ApplicationFiled: September 12, 2007Publication date: December 4, 2008Applicant: ZyStor Therapeutics, Inc.Inventors: Jonathan LeBowitz, John Maga
-
Publication number: 20050244400Abstract: Targeted acid alpha-glucosidase therapeutics that localize to the lysosome are provided. The targeted therapeutics include a therapeutic agent, GAA, and a targeting moiety that binds a receptor on an exterior surface of the cell, permitting proper subcellular localization of the targeted therapeutic upon internalization of the receptor. Nucleic acids, cells, and methods relating to the practice of the invention are also provided.Type: ApplicationFiled: February 10, 2005Publication date: November 3, 2005Applicant: ZyStor Therapeutics, Inc.Inventors: Jonathan LeBowitz, John Maga
